Our NavaRX medically supervised weight loss program features semaglutide to assist in achieving weight loss goals and consistent guidance from certified nutrition counselors
Among the most notable are MSDC-0160 (PNU-91325) and MSDC-0602K, which show potent insulin-sensitizing effects in preclinical 52,53,54 and clinical 53,55 studies despite exhibiting much reduced ability to bind and signal via PPAR 51
To minimize risks of delayed emergence from anesthesia, aspiration, aspiration pneumonitis, and conversion to intubation, ceasing GLP-1A 14 days before surgery is optimal
One of the most consequential changes in 2026 is the loss of exclusivity for semaglutide, beginning in early 2026 across major markets including India, China, Brazil, Turkey and Canada, with semaglutide having lost exclusivity in India on 20th March 2026